By product type (immunoglobulins, coagulation factor concentrate, albumin, protease inhibitors and other products.), application (neurology, immunology, hematology, critical care, pulmonology, hemato- oncology, rheumatology and others), processing technology (Ion- exchange chromatography , affinity chromatography, cryopreservation, ultrafiltration and microfiltration), mode(modern plasma fraction and traditional plasma fractionation), End user (Hospitals & clinics, clinical research laboratories academic institutions and others), Distribution channel (into direct tenders, third party distribution and others) , Countries(China, Japan, South Korea, Australia, India, Malaysia, Thailand, Singapore and rest of Asia Pacific ) Industry Trends and Forecast to 2028.
Market Analysis and Insights: Asia- Pacific Plasma Fractionation Market
Asia- Pacific Plasma Fractionation Market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 7.5%in the forecast period of 2021 to 2028 and is expected to reach USD 7,111.80 Million by 2028.
Plasma is a blood component, derives from whole blood by plasmapheresis and used for various therapeutic and medical applications. Human plasma is s source of numerous different proteins, however only a few of these proteins are useful for producing therapeutic plasma products . the process of separation, extraction, and purification of these proteins from the plasma is called fractionation process. The proteins extracted from the plasma are mainly categorized into classes such as immunoglobulins , coagulation factor concentrates, albumin , protease inhibitors, and others
Asia- Pacific plasma Fractionation market is growing with factors such as rise in respiratory diseases across the world, increase in aging population with blood-related ailments, and increasing usage of immunoglobulins. Increase in rare diseases that require the use of plasma therapy or plasma derivatives also acts as a major factor for the growth of the market. Increasing investment in research and development has also given a boom to the Asia- Pacific plasma fractionation market.
This Plasma Fractionation market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Asia- Pacific Plasma Fractionation Market Scope and Market Size
Asia- Pacific Plasma Fractionation Market, By product type (immunoglobulins, coagulation factor concentrate, albumin, protease inhibitors and other products.), application (neurology, immunology, hematology, critical care, pulmonology, hemato- oncology, rheumatology, and others), processing technology (Ion- exchange chromatography , affinity chromatography, cryopreservation, ultrafiltration, and microfiltration), mode(modern plasma fraction and traditional plasma fractionation), End user (Hospitals & clinics, clinical research laboratories academic institutions and others), Distribution channel (into direct tenders, third party distribution, and others). The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets. On the basis of product type, the plasma fractionation market is segmented into immunoglobulins, coagulation factor concentrate, albumin, protease inhibitors, and other products. Further, the Immunoglobulins have been segmented further into intravenous immunoglobulins, subcutaneous immunoglonbulins, and others. Coagulation factor concentrates are further subsegmented into factor VIII, Factor CI, Von willebrand factor, Prothrombin complex concentrate, fibrinogen concentrates, and factor XII. In 2021, immunoglobulin has the largest market share owing to the factors such as the high number of health benefits associated with immunomodulatory actions.
- On the basis of application, the plasma fractionation market is segmented into neurology, immunology, hematology, critical care, pulmonology, hemato- oncology, rheumatology and others. In 2021, Immunology has the largest market share owing to the factors such as increasing usage of plasma proteins in the treatment of immune deficiencies.
- On the basis of processing technology , the plasma fractionation market is segmented into Ion- exchange chromatography , affinity chromatography, cryopreservation, ultrafiltration and microfiltration. In 2021, Ion- exchange chromatography has the largest market share owing to the factor such as the high purification capability using ions by removing inorganic substances.
- On the basis of mode, the plasma fractionation market is segmented into modern plasma fraction and traditional plasma fractionation. In 2021, modern plasma fractions has the largest market share owing to the factors such as the employing the state of art equipment and production facilities for the plasma fractionation process.
- On the basis of End User, the plasma fractionation market is segmented into Hospitals & clinics, clinical research laboratories academic institutions and others. In 2021, hospitals & clinics has the largest market share due to improving infrastructure and health care facilities provided by hospitals, along with increasing off- label use of plasma fractionated products in hospitals to treat various diseases..
- On the basis of Distribution channel, the plasma fractionation market is segmented into direct tenders, third party distribution and others . In 2021, direct tenders has the largest market share due to. Increasing distribution through direct tenders from the manufacturers to the health care workers.
Asia- Pacific Plasma Fractionation Market: Country Level Analysis
Asia- Pacific Plasma Fractionation Market is analysed and market size information is provided by country, Type (Bioinsecticides, Biofungisides, Bionematicides, Bioherbicides and Others), Source (Microbials, Biochemical and Insects), Form (Dry and Liquid), Application (Foliar Application, Fertigation, Soil Treatment, Seed Treatment and Other), Category (Agriculture and Horticulture) and Crops as referenced above.
The countries covered in the Asia- Pacific Plasma Fractionation Market report are China, Japan, South Korea, Australia, India, Malaysia, and others
China is dominating in the Asia- Pacific Plasma Fractionation Market with the highest CAGR as the region has more awareness about the extensive benefits of the plasma.
Japan is dominating in the Asia- Pacific Plasma Fractionation market due to increase in the demand for Plasma Fractionation and growing concern over the human health.
South Korea is dominating the market with the highest share due to the geriatric population and immune deficiency diseases.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia- Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Rising Demand of Plasma Fractionation in Agriculture
Asia- Pacific Plasma Fractionation Market also provides you with detailed market analysis for every country growth in the industry with sales, components sales, impact of technological development in Plasma Fractionation, and changes in regulatory scenarios with their support for the Plasma Fractionation Product market. The data is available for historic period 2012-2018.
Competitive Landscape and Asia- Pacific Plasma Fractionation Market Share Analysis
Asia- Pacific Plasma Fractionation Market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, India presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to Asia- Pacific Plasma Fractionation Market.
Some of the major players operating in the plasma fractionation market are SL plasma, Grifols S.A., Octapharma, Kendrion S.P.A, BPL Inc, Sanquin, Biotest AG, LFB S.A., Japan Blood products organization, china biologics product Holdings Inc.,, Green Cross corp, Shanghai Raas, Takeda pharmaceutical company limited, Bioproducts laboratory Ltd, Novasep Inc, Pall corporation, Kabafusion , Sichuan Yuanda shuyang pharmaceutical Co., ltd, Bharat serums and vaccines limited, SK plasma, Centurion pharma, Ntas biopharmaceuticals , Merck KgAa, Boccard and ADMA biologics.
Many product launches are also initiated by the companies worldwide which are also accelerating the growth of Asia- Pacific Plasma Fractionation Market.
For instance,
- In April 2020, Grifols launched 3- ml vial for Hyper RAB which is rabies immune globulin in the plasma fractionation market to help in the treatment of rabies cases across the world.
Collaboration, joint ventures and other strategies by the market players is enhancing the company footprints in the Plasma Fractionation market which also provides the benefit for organisation in its growth pace.
SKU-